Repligen Co. (NASDAQ:RGEN) Shares Sold by Hilltop National Bank

Hilltop National Bank lowered its position in shares of Repligen Co. (NASDAQ:RGEN) by 10.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 875 shares of the biotechnology company’s stock after selling 97 shares during the period. Hilltop National Bank’s holdings in Repligen were worth $126,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Toronto Dominion Bank boosted its stake in Repligen by 1.5% in the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 75 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in Repligen by 1.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock valued at $982,000 after acquiring an additional 89 shares in the last quarter. MML Investors Services LLC boosted its stake in Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after acquiring an additional 89 shares in the last quarter. GAMMA Investing LLC boosted its stake in Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 90 shares in the last quarter. Finally, Ballentine Partners LLC boosted its stake in Repligen by 6.2% in the third quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock valued at $269,000 after acquiring an additional 105 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Trading Up 0.1 %

NASDAQ RGEN opened at $154.86 on Friday. The stock has a market capitalization of $8.68 billion, a P/E ratio of -418.53, a P/E/G ratio of 4.64 and a beta of 0.97. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The firm has a 50-day moving average price of $146.77 and a 200 day moving average price of $143.29. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.23 earnings per share. Equities research analysts expect that Repligen Co. will post 1.54 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on RGEN shares. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Finally, Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $185.20.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.